Strong Revenue Growth:
Independent estimates point to continued ARR increases since 2022, with momentum remaining positive despite a slower pace than earlier hyper‑growth. Feedback suggests growth is ongoing and more disciplined rather than stagnating.
Product Line Growth:
Company materials describe hundreds of new capabilities and AI‑powered tools launched through 2024–2025, alongside expanded modules and integrations. This sustained shipping cadence indicates continued investment and expansion of the platform’s surface area.
Strategic Partnerships:
Named enterprise announcements include Novonesis adopting the platform across 1,500 scientists and an expanded collaboration with Moderna focused on AI‑driven research. These wins suggest ongoing enterprise adoption and deepening ties with marquee biopharma.
